- ►diabetesjournals.org [PDF] RE Ratner, IB Hirsch, JL Neifing, SK Garg, … - Diabetes care, 2000 - Am Diabetes Assoc The Diabetes Control and Complica- tions Trial (DCCT) (1) and other stud- ies
(2,3) provide conclusive evidence that maintaining tight glycemic control can
prevent or delay microvascular complica- tions in individuals with type 1 ... Cited by 346 - Related articles - BL Direct - All 8 versions
P Raskin, L Klaff, R Bergenstal, JP Halle, D … - Diabetes Care, 2000 - Am Diabetes Assoc C urrently available intermediately or long-acting insulin products used for
basal insulin treatment are associated with either pronounced insulin peaks
after injection, a duration of action that is too short to maintain ... Cited by 201 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org [PDF] TR Pieber, I Eugene-Jolchine, E Derobert - Diabetes Care, 2000 - Am Diabetes Assoc F rom the Department of Internal Medicine (T. R . P.), Diabetes and Metabolism,
Karl-Franzens University, Graz, Austria; and Hoechst Marion Roussel (IE-J., ED),
Paris, France. A dd ress correspondence and reprint requests to Thomas R. ... Cited by 165 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org [PDF] L Heinemann, R Linkeschova, K Rave, B … - Diabetes care, 2000 - Am Diabetes Assoc From the Department of Metabolic Diseases and Nutrition, the World Health
Organization Collaborating Cen- tre for Diabetes, Heinrich-Heine University,
Düsseldorf, Germany. Address correspondence and reprint requests to Lutz ... Cited by 274 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org [PDF] M Lepore, S Pampanelli, C Fanelli, F Porcellati … - Diabetes, 2000 - Am Diabetes Assoc To compare the pharmacokinetics/dynamics of the long- acting insulin analog
glargine with NPH, ultralente, and continuous subcutaneous (SC) infusion of
insulin lispro (continuous subcutaneous insulin infusion [CSII]), 20 ... Cited by 514 - Related articles - BL Direct - All 7 versions
- Free from Publisher J Rosenstock, SL Schwartz, CM Clark Jr, GD … - Diabetes Care, 2001 - 万方数据资源系统 OBJECTIVE: To determine the safety and efficacy of the long-acting analog
insulin glargine compared with NPH insulin in patients with type 2 diabetes who
were previously treated with insulin alone. RESEARCH DESIGN AND METHODS: A ... Cited by 345 - Related articles - BL Direct - All 5 versions
P Rossetti, S Pampanelli, C Fanelli, F … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Mean daily blood glucose was lower with dinnertime glargine (7.5 ±
0.2 mmol/l) or bedtime glargine (7.4 ± 0.2 mmol/l) versus NPH (8.3 ± 0.2
mmol/l) (P < 0.05). A greater percentage of blood glucose values were at ... Cited by 121 - Related articles - BL Direct - All 5 versions
- ►viamedica.pl [PDF] - Free from Publisher P Vague, JL Selam, S Skeie, I De Leeuw, JWF … - Diabetes Care, 2003 - Am Diabetes Assoc 1 Hôpital de la Timone, Service Nutrition Endocrinologie et Maladies
Metabolique, Marseilles, France 2 Hotel Dieu, Service de Diabétologie, Paris,
France 3 Hjertelaget Research Foundation, Stavanger, Norway 4 Department of ... Cited by 232 - Related articles - BL Direct - All 8 versions
P Raskin, RA Guthrie, L Leiter, A Riis, L … - Diabetes Care, 2000 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS — This was a randomized open-label parallel-group
study conducted at 59 centers in the US and Canada. Sub- jects with type 1
diabetes were treated with IAsp or HI as part of an intensive insulin reg- ... Cited by 196 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org NP Murphy, SM Keane, KK Ong, M Ford-Adams … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Compared with R/NPH therapy, LIS/GLAR was associated with lower mean
blood glucose levels (LIS/GLAR versus R/NPH): fasting (8.0 vs. 9.2 mmol/l, P <
0.0001), 2 h postbreakfast (8.1 vs. 10.7 mmol/l, P < 0.0005), prelunch (8.9 ... Cited by 118 - Related articles - BL Direct - All 6 versions
